4.8 Article

Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia

期刊

CANCER CELL
卷 23, 期 2, 页码 200-214

出版社

CELL PRESS
DOI: 10.1016/j.ccr.2013.01.011

关键词

-

资金

  1. Cole Foundation
  2. University Clinic of Essen
  3. Max-Eder fellowship from the German Cancer fund
  4. University of Cincinnati Cancer Therapeutics T32 training grant [T32-CA117846]
  5. Leukaemia and Lymphoma Research UK
  6. CancerFree Kids
  7. Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  8. Leukemia and Lymphoma Society of America
  9. NIH [CA105152, CA159845]
  10. Center of Excellence in Molecular Hematology [DK090971]
  11. Canada Research Chair (Tier 1)
  12. Canadian Institutes of Health Research (CIHR) [MOP-84238, MOP-111011]
  13. BBSRC [BB/I00050X/1] Funding Source: UKRI
  14. Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish
  15. Cancer Research UK [12765] Funding Source: researchfish
  16. Medical Research Council [MC_PC_12009] Funding Source: researchfish
  17. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [G0900729/1] Funding Source: researchfish

向作者/读者索取更多资源

Most patients with acute lymphoblastic leukemia (ALL) fail current treatments highlighting the need for better therapies. Because oncogenic signaling activates a p53-dependent DNA damage response and apoptosis, leukemic cells must devise appropriate countermeasures. We show here that growth factor independence 1 (Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses and lowers the threshold for p53-induced cell death. Specifically, Gfi1 restricts p53 activity and expression of proapoptotic p53 targets such as Box, Noxa (Pmaip1), and Puma (Bbc3). Subsequently, Gfi1 ablation cures mice from leukemia and limits the expansion of primary human T-ALL xenografts in mice. This suggests that targeting Gfi1 could improve the prognosis of patients with T-ALL or other lymphoid leukemias.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据